Clinical Trial Update: A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma [Phase 2]

View source ↗

Summary

This entry reports a Phase 2 clinical trial evaluating EZN-2208 with or without cetuximab in patients with metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• EZN-2208

Snippet

Sponsor: Enzon Pharmaceuticals, Inc. | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN